Binovi Technologies to bring its vision therapy technology platform to North American classrooms as it enters the K-12 education space
Students will use Binovi’s technology-driven vision training protocols to develop and strengthen literacy skills
Sector
Health
1090 stories · page 49 of 55
Codebase Ventures completes final tranche of non-brokered private placement, raising proceeds of $135,000
The company said the net proceeds from the private placement will be used for general working capital and to fund future investments
Binovi Technologies names former White House Fellow Eric Phillips as strategic advisor
Phillips is a former advisor on sustainable development for the government of Guyana, and the CEO of the Green Guyana Expo and International Business Summit
MindMed engages renowned psychedelic-assisted therapy expert Dr Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy
Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland and has served as the President of the Swiss Medical Society for Psycholytic Therapy since 1997
MindMed says dosing concluded in Phase 1 study of its 18-MC molecule which was well tolerated in humans
MindMed co-founders and co-CEOs Stephen Hurst and JR Rahn said: “We are very pleased with the initial dosing outcome of this Phase 1 SAD study"
Champignon files business acquisition reports, adds CEO Roger McIntyre to its board
The filings are part of Champignon’s commitment to cooperate with the British Columbia Securities Commission and complete its disclosure review in a timely fashion
Champignon Brands says board decides against rebranding and changing company’s name
The board continues to review options for marketing and branding of the company to represent its consumer-packaged goods business
MagicMed Industries files provisional patent covering psychedelic derivatives
The company expects the filing to be the first in a series of applications that together are designed to protect its portfolio of novel derivatives known as the Psybrary
SUDA Pharmaceuticals to continue focus on cancer, insomnia treatments
SUDA had been progressing towards a proposed material licensing transaction in relation to a cancer therapy technology from a leading US cancer research institute.
Champignon Brands CEO Dr Roger McIntyre authors studies appearing in two leading scientific journals
The articles, looking at safety and efficacy of ketamine as a mental health therapy, were co-authored in conjunction with the Canadian Rapid Treatment Centre of Excellence
Champignon Brands revamps its brand identity to better reflect its scientific focus on psychedelic medicine
The firm is changing its name to Apotheosis Scientific Ltd and spinning out its consumer packaged goods division
Champignon Brands closes C$15 million financing to fund North American ketamine clinical expansion plans
The psychedelic healthcare company sold a total of 17,647,500 units priced at C$0.85
Champignon selects Dalriada Drug Discovery to advance its new chemical entity IP portfolio
Dalriada said it was “excited” to support Champignon’s work in advancing the therapeutic applications of ketamine and psilocybin derivatives
Champignon Brands retains financial marketing service to help raise awareness of North American clinical expansion
Champignon also announced a voluntary share lockup of 17.84 million shares
Champignon Brands adds workplace mental health expert Dr Bill Wilkerson to its board of directors
Wilkerson spearheaded a 14-year-long Canadian initiative to recruit major employers to support employee mental health and previously served as president of Liberty Health
Does ATAI Life Sciences' 'biotech platform' provide the antidote to traditional drug discovery model?
Set up two years ago, it has attracted more than US$100mln in Series A and B funding that has brought in an impressive roster of early investors, including Peter Thiel, the co-founder of both PayPal and Palantir
Champignon Brands sponsors non-profit coalition seeking Psilocybin access for palliative cancer patients
Based in British Columbia, the TheraPsil coalition encompasses healthcare professionals, policy-makers and community leaders aiming to promote access to psychedelic-assisted therapy for those in medical need
Champignon Brands inks deal for California's Wellness Clinic of Orange County as part of North American expansion strategy
The deal represents a key leap forward in the company's strategy to open five new ketamine clinics in the US this year
Champignon Brands to raise $10 million for North American ketamine clinic expansion
The Vancouver-based company plans to open at least five new ketamine clinics in the US by the end of 2020
Champignon Brands appoints psychiatry and pharmacology professor, Roger McIntyre as new CEO
Prior to joining Champignon, McIntyre implemented and developed the Canadian Rapid Treatment Centre of Excellence, the country's first-ever rapid-onset treatment centre for persons with mood disorders